Free Trial

Nautilus Biotechnology (NAUT) News Today

Nautilus Biotechnology logo
$2.34 +0.10 (+4.46%)
(As of 11/20/2024 ET)
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
Q3 2024 Nautilus Biotechnology Inc Earnings Call
TD Cowen Keeps Their Buy Rating on Nautilus Biotechnolgy (NAUT)
Nautilus Biotechnology, Inc. stock logo
Nautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on Tuesday
Nautilus Biotechnology (NASDAQ:NAUT) will be releasing earnings before the market opens on Tuesday, October 29, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=633846)
Nautilus Biotechnology Insider Ups Holding During Year
Nautilus Biotechnology, Inc. stock logo
Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. During the same quarter last year, the firm posted ($0.13) earnings per share.
Nautilus Down on Releasing Q2 Numbers
Nautilus Biotechnology, Inc. stock logo
Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 2.5%
Nautilus Biotechnology (NASDAQ:NAUT) Shares Down 2.5%
Nautilus Biotechnology, Inc. stock logo
Nautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at Guggenheim
Guggenheim initiated coverage on shares of Nautilus Biotechnology in a research note on Thursday. They set a "buy" rating and a $6.00 target price for the company.
Nautilus Biotechnology, Inc. stock logo
Perceptive Advisors LLC Buys 3,483,060 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)
Perceptive Advisors LLC grew its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 38.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,594,211 shares of the company's sto
Nautilus Biotechnology, Inc. stock logo
Nautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at Jefferies Financial Group
Jefferies Financial Group started coverage on shares of Nautilus Biotechnology in a research report on Monday. They set a "hold" rating and a $3.00 price target for the company.
Q1 2024 Nautilus Biotechnology Inc Earnings Call
Nautilus Biotechnology Inc Ordinary Shares NAUT
Nautilus Biotechnology, Inc. stock logo
Insider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Acquires $34,204.96 in Stock
Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal M. Patel purchased 12,044 shares of the stock in a transaction dated Monday, March 11th. The shares were purchased at an average price of $2.84 per share, with a total value of $34,204.96. Following the completion of the acquisition, the chief executive officer now owns 10,064,488 shares of the company's stock, valued at $28,583,145.92. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
Q4 2023 Nautilus Biotechnology Inc Earnings Call
Get Nautilus Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

NAUT Media Mentions By Week

NAUT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NAUT
News Sentiment

0.00

0.45

Average
Medical
News Sentiment

NAUT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NAUT Articles
This Week

0

1

NAUT Articles
Average Week

Get Nautilus Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NAUT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners